🌐 Ewelina Palmer is a dynamic force as the Director of Patient Centered Science at AstraZeneca, a global pharmaceutical leader. With unwavering passion, she spearheads strategic and scientific initiatives, meticulously crafting a landscape that prioritizes the patient journey. Ewelina specializes in generating invaluable evidence of patient experiences across the entire product lifecycle. Her visionary leadership ensures a holistic understanding of treatments, enhancing the intersection of science and humanity. 🚀 As a seasoned professional, she brings a wealth of expertise to revolutionize the pharmaceutical narrative, placing patient well-being at the forefront. Ewelina Palmer: A trailblazer in shaping the future of patient-centered care. 👩⚕️💡
Professional Profile:
Scopus
Education:
👩🎓 Dr. Ewelina Palmer, a distinguished scholar, holds a Ph.D. in Psychology (Affective Neuroscience) from the University of Reading, UK, awarded in 2017. 🧠 Her academic journey includes a Master of Science in Cognitive Neuroscience from the same institution in 2013 and a Master of Arts in Psychology from the University of Aberdeen, UK, in 2012. 🌍 Driven by a passion for understanding the intricate workings of the human mind, Ewelina’s educational milestones reflect her commitment to advancing knowledge in the fields of affective neuroscience and cognitive studies. 🎓✨ She is a beacon of academic excellence, contributing significantly to the realm of psychological research.
Experience:
🧠 Dr. Ewelina Palmer, a trailblazing expert in Patient Centered Science, currently serves as the Director at AstraZeneca since 2021. 🌐 With a rich background, she previously contributed as a Clinical Outcomes Assessment Consultant at Access Consulting, Parexel International (2019-2021) and as a Patient Centred Outcomes Associate Consultant at OPEN Health UK (2018-2019). 🌟 Ewelina’s academic prowess extends to her roles as an Honorary Researcher at the University of Reading and a Visiting Scientist at Harvard Medical School. 🏫 Her multifaceted experience includes teaching at the University of Reading and managing pharmaceutical vendors, showcasing her holistic approach to patient-centric project development. 🚀👩🔬
Publication Top Note:
- 📚 Publication: “Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP)–cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom”
- 📅 Year: 2021
- 👥 Authors: Holmes, S., Podger, L., Bottomley, C., … Bailey, K.M.A., Chandler, F.
- 📚 Publication: “Dimensional anhedonia and the adolescent brain: Reward and aversion anticipation, effort and consummation”
- 📅 Year: 2019
- 👥 Authors: Rzepa, E., McCabe, C.
- 📚 Publication: “Anhedonia and depression severity dissociated by dmPFC resting-state functional connectivity in adolescents”
- 📅 Year: 2018
- 👥 Authors: Rzepa, E., McCabe, C.
- 📚 Publication: “Bupropion Administration Increases Resting-State Functional Connectivity in Dorso-Medial Prefrontal Cortex”
- 📅 Year: 2017
- 👥 Authors: Rzepa, E., Dean, Z., McCabe, C.
- 📚 Publication: “Blunted neural response to anticipation, effort and consummation of reward and aversion in adolescents with depression symptomatology”
- 📅 Year: 2017
- 👥 Authors: Rzepa, E., Fisk, J., McCabe, C
- 📚 Publication: “Decreased anticipated pleasure correlates with increased salience network resting state functional connectivity in adolescents with depressive symptomatology”
- 📅 Year: 2016
- 👥 Authors: Rzepa, E., McCabe, C.
- 📚 Publication: “The CB1 neutral antagonist tetrahydrocannabivarin reduces default mode network and increases executive control network resting state functional connectivity in healthy volunteers”
- 📅 Year: 2016
- 👥 Authors: Rzepa, E., Tudge, L., McCabe, C.